Clinical Trial Update: A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IBI362 versus semaglutide in Chinese adults who are overweight or obese with metabolic dysfunction-associated fatty liver disease (MAFL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Fatty Liver Disease
• Obesity

Drugs mentioned

• IBI362
• semaglutide (semaglutide)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | Status: RECRUITING